Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patientsSteven E. Schumacher, Rameen Beroukhim, Byoung Yong Shim et al.|PLoS ONE|2017Cited by 61
1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort ADaniel V.T. Catenacci, Y-K. Kang, Hyun Cheol Chung et al.|Annals of Oncology|2021Cited by 14
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung‐Ju Ahn, Maen Hussein, Igor Bondarenko et al.|Journal of Thoracic Oncology|2023Cited by 11
658 A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancerPaul Rhee, Michael Chisamore, Do‐Youn Oh et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.Do‐Youn Oh, Young Su Noh, Min-Hee Ryu et al.|Journal of Clinical Oncology|2025Cited by 0